ESR1 and myeloid leukemia: The cytotoxic potential of the synthesized compounds was investigated using the MTT assay after 72 h incubation with a panel of human and murine cancer cell lines, including colorectal carcinoma (HCT116), estrogen receptor-positive breast adenocarcinoma (MCF-7), triple-negative breast adenocarcinoma (MDA-MB-231), epidermoid carcinoma (KB3-1), myeloid leukemia (K562), and glioblastoma (U373), and mouse breast carcinoma (4T1) cells.